<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Commenti a: Diabete 2, maxi-studio promuove pillola Glp-1 orforglipron﻿ All&#8217;Easd di Milano e su Lancet i dati del più grande trial sul primo Glp-1 orale di Lilly, &#8216;conferma sicurezza cardiovascolare, controllo glicemia e calo peso&#8217;	</title>
	<atom:link href="https://www.lafrecciaweb.it/2026/10/01/diabete-2-maxi-studio-promuove-pillola-glp-1-orforglipron-alleasd-di-milano-e-su-lancet-i-dati-del-piu-grande-trial-sul-primo-glp-1-orale-di-lilly-conferma-sicurezza-cardiovascolare-co/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.lafrecciaweb.it/2026/10/01/diabete-2-maxi-studio-promuove-pillola-glp-1-orforglipron-alleasd-di-milano-e-su-lancet-i-dati-del-piu-grande-trial-sul-primo-glp-1-orale-di-lilly-conferma-sicurezza-cardiovascolare-co/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=diabete-2-maxi-studio-promuove-pillola-glp-1-orforglipron-alleasd-di-milano-e-su-lancet-i-dati-del-piu-grande-trial-sul-primo-glp-1-orale-di-lilly-conferma-sicurezza-cardiovascolare-co</link>
	<description>la velocità dell&#039;informazione</description>
	<lastBuildDate>Thu, 01 Oct 2026 09:23:00 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.9</generator>
</channel>
</rss>
